VIVA IVD’s purpose is to save lives by reducing in-hospital mortality due to sepsis, additionally its mission is to develop advanced and easy-to-use devices that solve the current problem of stratification in patients with sepsis and other inflammatory processes; as well as contribute to the development of new therapies using cutting-edge scientific knowledge in the area of ​​inflammasomes. In clinical practice, we hope to reduce mortality by 25% to 40%. The medical device for in vitro diagnostics (IVD for its acronym in English, In Vitro Diagnostics) in Lab-on-a-chip format for early detection of NLRP3 inflammasome activation (compact, automated, disposable cartridge equipment), said The product is designed to serve mainly the Intensive Care Unit (ICU) and the Resuscitation and Anesthesiology Service. In conclusion, sepsis requires much more than a quick diagnosis, it requires knowledge of the mechanisms involved in order to guide the most effective treatment in each patient early before the damage (and therefore the risk of sequelae or death) occurs. extend; and so that such treatments can be investigated with hitherto unknown efficacy.

Year of incorporation:
2021

Tax ID:
B16937435

Postal address:
Parque Científico de Murcia (PCMu), Ctra. de Madrid, Km. 388 Edificio T, 1ª Planta, 30100 Espinardo Murcia

Contact person:
Joaquín Gomez Moya
joaquin.gomez@vivaivd.com
646982008

Biocompany Area:
Health
Net Worth €K:
1.119€

Number of employees:
6

Invoicing::
–

Investment raised €K:
1.200€

Valuation round €K:
3.500€

Product/Service:
Compact device

Therapeutic area:
Sepsis

Indication/Solution:
specific oligomers related to the activation or not of the nlrp3 inflammasome

Phase / TRL:
TRL4

Geographical location of studies:
Spain